Table 4.
Characteristics of subgroup with greater bleeding than ischemic risk.
| Characetristics | Bleeding Risk >Ischemic Risk (n = 294) |
Ischemic Risk ≥ Bleeding Risk (n = 9112) |
|---|---|---|
|
| ||
| Age (years), mean±SD | 64.5±10.1 | 62.3±10.6 |
|
| ||
| BMI (kg/m2), mean±SD | 24.8±3.5 | 28.2±4.7 |
|
| ||
| Male | 2.4% | 78.5% |
|
| ||
| Diabetes | 0.3% | 29.0% |
|
| ||
| Smoking | 10.9% | 25.1% |
|
| ||
| Prior MI | 0% | 20.5% |
|
| ||
| Prior CABG | 0% | 5.5% |
|
| ||
| Prior CHF | 0.7% | 3.4% |
|
| ||
| Creatinine clearance | ||
| ≥ 60 mL/min | 85.7% | 79.3% |
| 30–59 mL/min | 14.3% | 13.5% |
| < 30 mL/min | 0% | 0.7% |
| Missing | 0% | 6.5% |
|
| ||
| Presentation | ||
| Stable | 79.6% | 56.6% |
| NSTEACS | 20.4% | 35.5% |
| STEMI | 0% | 7.9% |
| Total stent length (mm), mean±SD | 19.4±8.1 | 31.7±19.4 |
|
| ||
| Drug-eluting stent used | ||
|
| ||
| E-ZES | 91.2% | 53.8% |
BMI, body-mass index; MI, myocardial infarction; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; NSTEACS, non-ST elevation acute coronary syndrome; STEMI, ST elevation myocardial infarction, E-ZES, Endeavor zotarolimus eluting stent